What is HC Wainwright’s Estimate for CAPR Q3 Earnings?

Capricor Therapeutics, Inc. (NASDAQ:CAPR) – Equities researchers at HC Wainwright reduced their Q3 2026 EPS estimates for shares of Capricor Therapeutics in a research report issued on Friday, August 14th. HC Wainwright analyst J. Pantginis now anticipates that the biotechnology company will earn ($0.73) per share for the quarter, down from their prior forecast of ($0.63). HC Wainwright currently has a “Neutral” rating on the stock. The consensus estimate for Capricor Therapeutics’ current full-year earnings is ($1.62) per share. HC Wainwright also issued estimates for Capricor Therapeutics’ Q4 2026 earnings at ($0.73) EPS, FY2026 earnings at ($2.75) EPS and FY2027 earnings at ($2.84) EPS.

Capricor Therapeutics (NASDAQ:CAPR) last posted its quarterly earnings results on Friday, August 14th. The biotechnology company reported ($0.70) EPS for the quarter, missing analysts’ consensus estimates of ($0.59) by ($0.11).

Other analysts also recently issued reports about the company. Roth Capital downgraded Capricor Therapeutics from a “buy” rating to a “neutral” rating and set a $7.00 target price for the company. in a research report on Monday, July 27th. Oppenheimer reiterated a “market perform” rating on shares of Capricor Therapeutics in a research note on Monday, July 27th. Wall Street Zen lowered Capricor Therapeutics from a “sell” rating to a “strong sell” rating in a report on Saturday, August 1st. Piper Sandler downgraded shares of Capricor Therapeutics from an “overweight” rating to a “neutral” rating and set a $2.00 price objective on the stock. in a report on Thursday, July 30th. Finally, Maxim Group downgraded shares of Capricor Therapeutics from a “buy” rating to a “hold” rating in a research note on Thursday, July 30th. One investment analyst has rated the stock with a Buy rating, nine have issued a Hold rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat.com, the company has a consensus rating of “Hold” and a consensus target price of $29.15.

Capricor Therapeutics Trading Up 12.0%

Capricor Therapeutics stock opened at $7.45 on Tuesday. The business’s 50 day simple moving average is $17.81 and its 200 day simple moving average is $25.28. Capricor Therapeutics has a 12 month low of $2.96 and a 12 month high of $40.37. The company has a market cap of $431.43 million, a price-to-earnings ratio of -3.04 and a beta of 0.54.

Institutional Inflows and Outflows

Institutional investors have recently made changes to their positions in the company. Russell Investments Group Ltd. boosted its stake in Capricor Therapeutics by 122.2% during the third quarter. Russell Investments Group Ltd. now owns 5,066 shares of the biotechnology company’s stock valued at $37,000 after buying an additional 2,786 shares during the period. ACT Capital Management LLC bought a new position in Capricor Therapeutics in the 4th quarter worth about $43,000. KBC Group NV bought a new position in Capricor Therapeutics in the 1st quarter worth about $44,000. Tower Research Capital LLC TRC raised its holdings in shares of Capricor Therapeutics by 280.8% in the 2nd quarter. Tower Research Capital LLC TRC now owns 6,748 shares of the biotechnology company’s stock valued at $67,000 after acquiring an additional 4,976 shares in the last quarter. Finally, Regal Investment Advisors LLC purchased a new stake in shares of Capricor Therapeutics in the 3rd quarter valued at about $92,000. Institutional investors own 21.68% of the company’s stock.

Insider Transactions at Capricor Therapeutics

In other Capricor Therapeutics news, CFO Anthony Bergmann sold 24,100 shares of the stock in a transaction that occurred on Thursday, June 25th. The shares were sold at an average price of $30.38, for a total value of $732,158.00. Following the sale, the chief financial officer directly owned 11,223 shares in the company, valued at $340,954.74. This represents a 68.23% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. In the last 90 days, insiders have sold 25,000 shares of company stock valued at $759,158. Corporate insiders own 9.20% of the company’s stock.

Trending Headlines about Capricor Therapeutics

Here are the key news stories impacting Capricor Therapeutics this week:

• Negative Sentiment: A securities-fraud class action has been filed against Capricor and certain executives. The lawsuit alleges that the company made material misstatements or omissions about Deramiocel, the HOPE-3 clinical trial’s statistical analysis plan, FDA compliance, and the integrity of data supporting its Biologics License Application. The allegations relate to a previously reported 64% stock decline; they have not been proven in court. Capricor securities-fraud lawsuit
• Negative Sentiment: Multiple law firms are publicizing the class action and urging investors who purchased CAPR shares between December 17, 2025, and July 26, 2026, to seek lead-plaintiff status by late September. The repeated litigation notices may keep legal and clinical-data concerns in focus, potentially limiting buying interest. Capricor class-action deadline
• Negative Sentiment: HC Wainwright lowered its EPS forecasts across several periods while maintaining a Neutral rating. Estimates were reduced to losses of $0.73 per share for both the third and fourth quarters of 2026, $2.75 for fiscal 2026, and $2.84 for fiscal 2027, from prior forecasts of $0.63, $0.60, $2.43, and $2.57, respectively. The revisions reinforce expectations for sustained cash burn and larger losses. HC Wainwright Capricor estimates
• Neutral Sentiment: Investor concerns were also amplified by reports that Capricor’s recent second-quarter earnings call did not include a management question-and-answer session with analysts, reducing near-term clarity on the company’s clinical, regulatory, and financing outlook. Capricor Q2 earnings and lawsuit update

Capricor Therapeutics Company Profile

Capricor Therapeutics, Inc is a clinical-stage biotechnology company focused on the development of cell and exosome-based therapeutics for cardiovascular and rare diseases. Headquartered in Beverly Hills, California, the company leverages proprietary cardiosphere-derived cell (CDC) technology to address conditions characterized by inflammation, fibrosis, and tissue degeneration. Since its founding, Capricor has advanced its lead candidate through multiple clinical trials and has built a pipeline that spans both cell therapy and extracellular vesicle (exosome) platforms.

The company’s leading product candidate, CAP-1002, comprises allogeneic CDCs and is being evaluated in indications such as Duchenne muscular dystrophy (DMD) and COVID-19-related heart injury.